Noble Financial Estimates NanoViricides FY2026 Earnings

NanoViricides, Inc. (NYSE:NNVC) – Investment analysts at Noble Financial issued their FY2026 earnings per share estimates for NanoViricides in a report released on Monday, July 6th. Noble Financial analyst R. Leboyer expects that the company will post earnings of ($0.43) per share for the year. Noble Financial has a “Outperform” rating and a $6.00 price target on the stock. Noble Financial also issued estimates for NanoViricides’ Q4 2026 earnings at ($0.11) EPS, Q1 2027 earnings at ($0.10) EPS, Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.12) EPS, Q4 2027 earnings at ($0.13) EPS, FY2027 earnings at ($0.46) EPS, FY2028 earnings at $0.50 EPS and FY2029 earnings at $0.95 EPS.

NanoViricides Stock Performance

Shares of NYSE NNVC opened at $1.47 on Wednesday. NanoViricides has a 1 year low of $0.85 and a 1 year high of $2.23. The firm has a market cap of $33.79 million, a P/E ratio of -2.04 and a beta of 1.67. The stock has a fifty day moving average price of $1.46 and a two-hundred day moving average price of $1.21.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NNVC. Susquehanna International Group LLP grew its holdings in NanoViricides by 37.4% during the third quarter. Susquehanna International Group LLP now owns 52,217 shares of the company’s stock worth $75,000 after acquiring an additional 14,217 shares during the period. Geode Capital Management LLC lifted its holdings in NanoViricides by 9.4% in the 4th quarter. Geode Capital Management LLC now owns 174,371 shares of the company’s stock valued at $197,000 after acquiring an additional 14,944 shares during the last quarter. Miller Financial Services LLC bought a new position in shares of NanoViricides during the 4th quarter valued at about $81,000. Jane Street Group LLC acquired a new position in shares of NanoViricides in the 4th quarter worth approximately $140,000. Finally, State Street Corp grew its stake in shares of NanoViricides by 29.4% in the 4th quarter. State Street Corp now owns 54,206 shares of the company’s stock worth $61,000 after purchasing an additional 12,300 shares during the last quarter. Institutional investors own 10.30% of the company’s stock.

Key Headlines Impacting NanoViricides

Here are the key news stories impacting NanoViricides this week:

• Positive Sentiment: Noble Financial initiated coverage with an Outperform rating and a $6.00 price target, implying substantial upside from current levels and giving investors a bullish valuation anchor. Benzinga
• Positive Sentiment: The firm also issued long-term earnings estimates that turn positive by fiscal 2028 and fiscal 2029, suggesting analysts see a path toward meaningful profitability over time. MarketBeat NNVC
• Neutral Sentiment: NanoViricides said it is advancing NV-387 oral gummies toward a Phase II clinical trial for Ebola in the Democratic Republic of Congo, with a principal investigator and university support already lined up. This keeps the company’s antiviral pipeline in focus, but the trial still depends on regulatory approvals. Access Newswire
• Negative Sentiment: Despite the bullish target, Noble’s near-term estimates still show repeated losses per share through fiscal 2027, which underscores ongoing execution and funding risk for a clinical-stage biotech. MarketBeat NNVC

About NanoViricides

NanoViricides, Inc is a clinical-stage biotechnology company focused on the development of novel antiviral therapies using its proprietary nanomicelle technology. The company designs polymeric, virus-targeted nanoviricides that seek to neutralize viral pathogens by binding to specific viral surface proteins and destroying their structural integrity. NanoViricides’ platform is intended to offer broad-spectrum activity against a range of enveloped viruses, positioning it as a potential solution for both existing and emerging viral threats.

The company’s pipeline includes preclinical and early clinical candidates targeting seasonal and pandemic influenza strains, as well as investigational programs for coronaviruses, hepatitis, dengue, HIV and other viruses.